Articles from Merakris Therapeutics

Enrollment milestone and ongoing study to be highlighted at SAWC Fall 2025; Merakris expanding clinical trial site partnerships

Patent strengthens intellectual property for investigational new drug MTX-001 — Phase 2 clinical trial for chronic venous leg ulcers ongoing

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)

MTX-001, an investigational new drug, aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers

As CSO, Dr. Ilagan will continue to spearhead the advancement of cell-free biologic therapies from immunologically privileged tissues to regenerative medicine drugs for complex cutaneous wounds

Results from Part 1 of a two-part Phase 2 clinical trial demonstrate the efficacy and safety of a novel subcutaneous biologic for chronic venous leg ulcers

Cellular, Acellular, Matrix-like Products (CAMPs) Summit hosted first awards ceremony, and recognized Merakris Therapeutics’ Scientist in “Best Comparative Trial Award”.

Merakris aims to deliver a first-in-class drug and pioneer a new era within the wound care industry by commercializing regenerative medicine for hard-to-heal wounds

Merakris to showcase new Lyophilized Amnion Chorion Allograft at the Fall Symposium for Advanced Wound Care (SAWC) in Las Vegas at booth 440 on October 2-5, 2024.

Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024

RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.

Merakris Therapeutics to present poster at CAMPs Wound Care Summit in Miami, Florida

Clinical trial data will be presented at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it has fully enrolled the first part of a two-part clinical trial to evaluate the safety, effectiveness, and administration frequency of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid. The therapy is being studied to treat non-healing venous stasis ulcers (VSUs).

Extends Reach of Therapy for Dry Eye and Other Ocular Surface Disease Symptoms

RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its investigational new drug programs aimed at treating patients with chronic skin and tissue wounds that fail to heal properly.

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid in restoring, repairing and regenerating damaged tissue across a range of human diseases and disorders.

RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and efficacy of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid, for the treatment of non-healing venous stasis ulcers.